Rupatadine combined with ebastine for treatment of chronic urticaria: efficacy and impact on complement level and T lymphocytes

doi:10.3877/cma.j.issn.1674-0785.2023.02.014

Abstract

Abstract:

Objective

To evaluate the efficacy of rupatadine combined with ebastine in the treatment of chronic urticaria and explore their effect on complement levels and T lymphocytes.

Methods

One hundred and eighty patients with chronic urticaria admitted from January 2020 to May 2021 were prospectively selected. They were divided into either a control group or an observation group using the random number table method. The control group (n=89) was treated with ebastine alone, and the observation group (n=91) was treated with rupatadine combined with ebastine. The therapeutic effects were compared between the two groups.

Results

Pruritus (0.61±0.07) score, the number of wheals (0.56±0.08), erythema score (0.81±0.09), and total clinical symptom score (1.12±0.19) after 8 weeks of treatment, as well as the urticaria activity score after 4 (2.12±0.11) and 8 (0.76±0.12) weeks of treatment were significantly lower in the observation group than in the control group (P＜0.05). After 8 weeks of treatment, CD4+/CD8+ ratio (1.85±0.24), C3 [(0.65±0.15) g/L^-1], C4 [(0.37±0.05) g/L^-1], IFN-γ [(15.36±2.84) ng/ml], sVCAM-1 [(0.62±0.10) ng/L], LT [(53.34±5.22) pg/ml], IL-17 [(2.22±0.45) ng/L], and IL-4 [(15.86±2.36) pg/ml] were better in the observation group than in the control group (P＜0.05). In the observation group, the disease recovery rate after 4 weeks (58.24%), 6 weeks (73.63%), and 8 weeks (90.11%) of treatment were all significantly higher than those of the control group (P＜0.05).

Conclusion

Rupatadine combined with ebastine in patients with chronic urticaria can improve the levels of T lymphocytes and complements, and relieve symptoms such as itching, wheals, and erythema.

Key words: Rupatadine, Ebastine, Chronic urticaria, Complement level, T Lymphocytes

Yi Liu, Min Pan, Yao Chen. Rupatadine combined with ebastine for treatment of chronic urticaria: efficacy and impact on complement level and T lymphocytes[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(02): 189-194.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.02.014

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I02/189

Figures/Tables 7

组别	例数	性别［例（%）］		年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	病程（月， $x ¯$ ±s）
组别	例数	男性	女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	病程（月， $x ¯$ ±s）
观察组	91	56（61.54）	35（38.46）	37.34±6.52	21.23±2.15	16.53±3.59
对照组	89	47（52.81）	42（47.19）	36.62±7.59	20.82±2.59	15.89±2.41
t/χ²值		1.401		0.683	1.157	1.401
P值		0.237		0.495	0.249	0.163

组别	例数	性别［例（%）］		年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	病程（月， $x ¯$ ±s）
组别	例数	男性	女性	年龄（岁， $x ¯$ ±s）	体质量指数（kg/m²， $x ¯$ ±s）	病程（月， $x ¯$ ±s）
观察组	91	56（61.54）	35（38.46）	37.34±6.52	21.23±2.15	16.53±3.59
对照组	89	47（52.81）	42（47.19）	36.62±7.59	20.82±2.59	15.89±2.41
t/χ²值		1.401		0.683	1.157	1.401
P值		0.237		0.495	0.249	0.163

组别	红斑	风团数目	瘙痒	总分
观察组（91例）
治疗前	2.45±0.12	2.33±0.11	2.54±0.10	6.78±1.42
治疗后8周	0.81±0.09	0.56±0.08	0.61±0.07	1.12±0.19
前-后	1.84±0.26	2.13±0.18	2.03±0.10	5.54±0.15
对照组（89例）
治疗前	2.68±0.34	2.39±0.19	2.61±0.15	6.59±1.63
治疗后8周	1.32±0.15	1.47±0.22	1.63±0.22	3.87±0.27
前-后	1.02±0.10	1.18±0.14	1.16±0.05	3.32±0.17
t值	27.808	39.465	73.57	92.954
P值	＜0.001	＜0.001	＜0.001	＜0.001

组别	CD8+（%）	CD4+（%）	CD4+/CD8+	C3（g/L^-1）	C4（g/L^-1）
观察组（91例）
治疗前	31.45±4.68	30.12±2.29	1.01±0.09	1.87±0.65	0.92±0.22
治疗后8周	21.11±1.12	39.87±4.45	1.85±0.24	0.65±0.15	0.37±0.05
前-后	10.76±1.54	9.53±2.29	0.74±0.12	1.01±0.09	0.49±0.06
对照组（89例）
治疗前	31.67±4.54	30.34±2.54	1.05±0.07	1.89±0.52	0.95±0.20
治疗后8周	26.54±2.24	34.59±3.23	1.61±0.19	1.36±0.12	0.64±0.19
前-后	5.88±1.41	4.29±1.11	0.51±0.05	0.52±0.05	0.31±0.05
t值	22.160	19.465	16.717	45.014	21.840
P值	＜0.001	＜0.001	＜0.001	＜0.001	＜0.001

组别	例数	治疗前	治疗后4周	治疗后8周	F_时点	F_交互	F_组间
观察组	91	4.46±1.22	2.12±0.11	0.76±0.12	1240.124	5.380	126.072
对照组	89	4.59±1.19	3.79±0.36	1.75±0.54	1240.124	5.380	126.072
t值		0.724	42.282	17.064
P值		0.470	＜0.001	＜0.001	＜0.001	0.021	＜0.001

组别	IFN-γ（ng/ml）	sVCAM-1（ng/L）	LT（pg/ml）	IL-17（ng/L）	IL-4（pg/ml）
观察组（91例）
治疗前	3.45±1.25	2.58±1.39	112.29±12.35	4.18±1.36	48.65±4.36
治疗后8周	15.36±2.84	0.62±0.10	53.34±5.22	2.22±0.45	15.86±2.36
前-后	11.91±2.22	1.96±1.37	58.95±9.66	1.96±1.22	32.79±3.11
对照组（89例）
治疗前	3.37±1.33	2.67±1.42	112.38±12.41	4.56±1.42	48.52±4.42
治疗后8周	10.15±2.17	1.51±0.35	85.41±5.33	3.12±0.54	21.33±2.36
前-后	6.78±1.77	1.16±1.39	26.97±10.18	1.44±1.30	27.19±3.55
t值	17.099	3.889	21.618	2.762	11.270
P值	＜0.001	＜0.001	＜0.001	0.006	＜0.001

组别	例数	疾病控制率［例（%）］
组别	例数	治疗后4周	治疗后6周	治疗后8周
观察组	91	53（58.24）	67（73.63）	82（90.11）
对照组	89	38（42.70）	52（58.43）	70（78.65）
χ²值		Wald χ²_组别=5.337，Wald χ²_时点=73.378
P值		P_组别=0.021，P_时点＜0.001

参数	β值	标准错误	95% Wald置信区间		假设检验
参数	β值	标准错误	下限	上限	Wald卡方值	自由度	显著性
（截距）	1.312	0.2351	0.851	1.773	31.132	1	＜0.001
观察组	0.660	0.2859	0.100	1.221	5.337	1	0.021
对照组	0	-	-	-	-	-	-
治疗后4周	-1.623	0.1917	-1.999	-1.247	71.656	1	＜0.001
治疗后6周	-0.960	0.1624	-1.278	-0.642	34.938	1	＜0.001
治疗后8周	0	-	-	-	-	-	-

References 18

1	徐延峰, 杜威萍, 骆志成, 等. 枸地氯雷他定治疗慢性荨麻疹的疗效及对血清白细胞介素23和33、趋化因子PARC/CCL-18的影响 [J]. 中华皮肤科杂志, 2019, 52(5): 337-339.
2	李俊捧. 富马酸卢帕他定联合盐酸雷尼替丁胶囊治疗慢性荨麻疹的疗效观察 [J]. 中国医师杂志, 2019, 21(7): 1094-1095.
3	宋红娟, 王宝娟, 李秋梅, 等. 灭荨汤联合抗组胺药物治疗慢性荨麻疹疗效及安全性评价 [J]. 中华中医药学刊, 2018, 36(6): 1515-1519.
4	Frare RG, Singh AK. A Critical review of physicochemical properties and analytical methods applied to quantitative determination of ebastine [J]. Crit Rev Anal Chem, 2018, 48(2): 102-109.
5	邢春华, 蔡育兵, 丁菲, 等. 富马酸卢帕他定片治疗慢性特发性荨麻疹的有效性及安全性 [J]. 中国医院药学杂志, 2017, 37(13): 1271-1274.
6	赵辨. 中国临床皮肤病学 [M]. 南京: 江苏科学技术出版, 2010: 742-744.
7	张燕, 商婷. 咪唑斯汀联合复方甘草酸苷治疗慢性特发性荨麻疹的临床分析 [J].临床皮肤科杂志, 2012, 41(11): 695-698.
8	Mynek A, Zalewska-Janowska A, Martus P, et al. How toassess disease activity in patients with chronic urticaria [J]. Allergy, 2008, 63(6): 777-780.
9	冉春涛. 左西替利嗪联合依巴斯汀治疗慢性荨麻疹对实验室指标、临床症状积分的影响及临床疗效分析 [J]. 河北医药, 2016, 38(7): 1015-1017.
10	罗金成, 陈曙光, 刘文英, 等. 自体全血注射对自体血清皮肤试验阳性的难治性慢性自发性荨麻疹患者嗜碱性粒细胞FcεR Ⅰ与CD63表达的影响 [J]. 中华皮肤科杂志, 2019, 52(4): 241-247.
11	张小艳, 常贵珍, 周婉婷, 等. 富马酸卢帕他定片治疗慢性自发性荨麻疹临床观察 [J]. 中国中西医结合皮肤性病学杂志, 2018, 17(3): 245-247.
12	Pathania YS, Budania A. Comment on "Children with chronic urticaria can be effectively controlled with updosing second- generation antihistamines". [J]. J Am Acad Dermatol, 2020, 83(5): e363-e364.
13	张蕾, 贾立军, 芝佳, 等. 卢帕他定联合依巴斯汀治疗慢性荨麻疹的临床研究 [J]. 现代药物与临床, 2020, 35(7): 1364-1367.
14	陈再明, 吴事仁, 葛维维. 润燥止痒胶囊联合依巴斯汀(开思亭)治疗慢性荨麻疹疗效及对免疫因子水平的影响 [J]. 中华中医药学刊, 2020, 38(3): 4.
15	徐俊涛, 王莹, 王丽, 等. 麻黄附子细辛汤联合依巴斯汀治疗脾虚湿蕴证慢性自发性荨麻疹的临床疗效及安全性分析 [J]. 中国全科医学, 2019, 22(2): 142-145.
16	侯贻魁, 夏继宁, 钟梅, 等. 卢帕他定和咪唑斯汀治疗慢性荨麻疹疗效观察 [J]. 中华皮肤科杂志, 2017, 50(10): 754-755.
17	付旭晖, 吴丹丹, 臧馥兰, 等. 硒酵母联合富马酸卢帕他定片治疗慢性荨麻疹临床疗效观察 [J]. 中国皮肤性病学杂志, 2020, 34(4): 485-488.
18	Gabrielli S, Le M, Netchiporouk E, et al. Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines [J]. J Am Acad Dermatol, 2020, 82(6): 1535-1537.

[1]	Rui Yuan, Wenjia Hu, Xien Gui, Yajun Yan, Ling Feng, Hengning Ke, Yong Xiong, Rongrong Yang. Application of refined lymphocyte subsets detection on patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(02): 84-91.
[2]	Lumei Wang, Wanjiao Lu, Ruiling Mo, Bin Zhang, Junjie Li. Regulatory mechanism of Helicobacter pylori infection on peripheral interferon gamma and interleukin-4 in peripheral blood of patients with chronic urticaria [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(05): 504-507.
[3]	Peifeng Zhang, Meiyin Zou, Meihua Wang, Youyi Zhang. Research progress of Helper T lymphocytes 22 cells and their characteristic cytokine interleukin-22 [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(03): 257-260.
[4]	Weijie Zeng, Yan Liao, Yue Hu, Juanyuan Hu, Guifang Zeng, Zeqin Fu, Shiduo Wu, Xiao Liang, Changfeng Xie, Muyun Liu. Comparison of immunosuppressive ability of human umbilical cord mesenchymal stem cells against T and B lymphocytes before and after cryopreservation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2021, 11(04): 200-206.
[5]	Fanpu Ji, Na Huang, Shu Zhang, Zhifang Cai, An Jiang, Rui Zhou, Baohua Li, Song Ren, Zongfang Li. Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 232-236.
[6]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.
[7]	Junjie Hao, Jiangsheng Yang, Zufu Zhu, Zhiqiang Gao, Yuming Kong, Gang Li. Role of CD8⁺ T lymphocytes in pathogenesis of pneumonia after acute cerebral infarction [J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(12): 659-664.

Please choose a citation manager

Content to export